Nikolas Herold

Nikolas Herold

Assistant Professor | Docent
Visiting address: BioMedicum A4, Solnavägen 9, 17165 Solna
Postal address: K6 Kvinnors och barns hälsa, K6 Barnonkologi och Barnkirurgi Herold, 171 77 Stockholm

About me

  • Paediatrician (Paediatric Oncology, Astrid Lindgren's Children Hospital,
    Karolinska University Hospital)
    Associate Professor
    Before Sidney Farber introduced chemotherapy to treat childhood cancer at the
    end of the 1940s, paediatric cancers have been – with the exception of a
    small subset of patients that could be cured by radical surgery only –
    considered universally lethal, and any treatment had been considered
    unethical experiments prolonging the patients’ suffering. However,
    empirical combinations of several cytotoxic drugs have led to an overall cure
    rate of childhood cancer of 85%. Nevertheless, 15% of paediatric cancer
    patients still succumb to their disease despite heavy combination therapies,
    and the death toll for adult cancer patients (e.g. 70% for acute myeloid
    leukaemia in adults vs less than 30% in children) is far higher. As of today,
    one understands surprisingly little about how combined drugs exert their
    synergistic effects on a cellular and molecular level. My research sets out
    to understand why certain combinations of chemotherapies work for some, but
    not all patients with the same diagnosis. The overarching hypothesis that
    drives my research is that genetic factors exist that determine the extent of
    cellular and clinical drug synergy of two or more drugs (combination
    chemotherapy). Identification of these factors will not only allow to
    establish predictive biomarkers for combination chemotherapies, but also
    constitute the starting point for the development of drugs targeting cellular
    factors that block synergy of combination treatments. Alternatively, existing
    drugs might be combined in a different schedule that circumvents these
    cellular factors.
    Research Prize Jeanssons Foundations
    Tranlational prize of the Swedish Medical Association
    NOPHO-prize 2016, Stockholm, Sweden
    Docentur (KI), 2021
    Medical degree (Heidelberg, Germany, 2012)
    Medical license (Sweden), 2015
    Doctoral degree (Heidelberg, Germany), 2015


  • Aetiology of Langerhans Cell Histiocytosis (LCH)
    Translational Paediatric Oncology
    Nucleotide metabolism
    HIV infection and inflammation
    *Publikationer (urval)*
    Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of
    newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial. [1]
    Jädersten M, Lilienthal I, Tsesmetzis N, Lourda M, Bengtzén S, Bohlin A,
    Arnroth C, Erkers T, Seashore-Ludlow B, Giraud G, Barkhordar GS, Tao S,
    Fogelstrand L, Saft L, Östling P, Schinazi RF, Kim B, Schaller T, Juliusson
    G, Deneberg S, Lehmann S, Rassidakis GZ, Höglund M, Henter JI, Herold N
    /J Intern Med 2022 Aug
  • ():/
    A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of
    177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed
    High-Risk Neuroblastoma-LuDO-N. [2]
    Sundquist F, Georgantzi K, Jarvis KB, Brok J, Koskenvuo M, Rascon J, van
    Noesel M, Grybäck P, Nilsson J, Braat A, Sundin M, Wessman S, Herold N,
    Hjorth L, Kogner P, Granberg D, Gaze M, Stenman J
    /Front Pediatr 2022
  • 10():836230/
    Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not
    B-Cell Non-Hodgkin Lymphomas. [3]
    Xagoraris I, Farrajota Neves da Silva P, Kokaraki G, Stathopoulou K, Wahlin
    B, Österborg A, Herold N, Ng SB, Medeiros LJ, Drakos E, Sander B, Rassidakis
    /Cancers (Basel) 2022 Feb
  • 14(5):/
    Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma.
    Merrien M, Wasik AM, Ljung E, Morsy MHA, de Matos Rodrigues J, Carlsten M,
    Rassidakis GZ, Christensson B, Kolstad A, Jerkeman M, Ek S, Herold N, Wahlin
    BE, Sander B
    /Virchows Arch 2022 Mar
  • 480(3):655-666/
    Response to mitogen-activated protein kinase inhibition of neurodegeneration
    in Langerhans cell histiocytosis monitored by cerebrospinal fluid
    neurofilament light as a biomarker: a pilot study. [5]
    Henter JI, Kvedaraite E, Martín Muñoz D, Cheng Munthe-Kaas M, Zeller B,
    Nystad TA, Björklund C, Donnér I, Lourda M, Zetterberg H, Blennow K, Herold
    N, Gavhed D, von Bahr Greenwood T
    /Br J Haematol 2022 01
  • 196(1):248-254/
    Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin
    Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk
    Neuroblastoma Cell Lines. [6]
    Ödborn Jönsson L, Sahi M, Lopez-Lorenzo X, Keller FL, Kostopoulou ON,
    Herold N, Ährlund-Richter L, Shirazi Fard S
    /Int J Mol Sci 2021 Apr
  • 22(7):/
    Expression of the novel tumour suppressor sterile alpha motif and HD
    domain-containing protein 1 is an independent adverse prognostic factor in
    classical Hodgkin lymphoma. [7]
    Xagoraris I, Vassilakopoulos TP, Drakos E, Angelopoulou MK, Panitsas F,
    Herold N, Medeiros LJ, Giakoumis X, Pangalis GA, Rassidakis GZ
    /Br J Haematol 2021 Feb
  • ():/
    Effects of PI3K and FGFR inhibitors alone and in combination, and
    with/without cytostatics in childhood neuroblastoma cell lines. [8]
    Holzhauser S, Lukoseviciute M, Papachristofi C, Vasilopoulou C, Herold N,
    Wickström M, Kostopoulou ON, Dalianis T
    /Int J Oncol 2021 Jan
  • ():/
    Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance
    in Osteosarcoma: A Review of Current and Future Strategies. [9]
    Lilienthal I, Herold N
    /Int J Mol Sci 2020 Sep
  • 21(18)/
    Pharmacological strategies to overcome treatment resistance in acute myeloid
    leukemia: increasing leukemic drug exposure by targeting the resistance
    factor SAMHD1 and the toxicity factor Top2β. [10]
    Herold N
    /Expert Opin Drug Discov 2020 Aug
  • ():1-5/
    Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity
    enhancing cytarabine efficacy. [11]
    Rudd SG, Tsesmetzis N, Sanjiv K, Paulin CB, Sandhow L, Kutzner J, /et al/
    /EMBO Mol Med 2020 Jan
  • ():e10419/
    Evidence for SAMHD1 Tumor Suppressor Functions in Acute Myeloid Leukemia.
    Schaller T, Herold N
    /Acta Haematol. 2019 Jul
  • ():1-2/
    Overexpression of the Interferon-Inducible Isoform 4 of NCOA7 Dissects the
    Entry Route of Enveloped Viruses and Demonstrates that HIV Enters Cells via
    Fusion at the Plasma Membrane. [13]
    Herold N
    /Viruses 2019 01
  • 11(2):/
    Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts
    correlates with improved outcome upon consolidation chemotherapy with
    high-dose cytarabine-based regimens. [14]
    Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, /et
    /Blood Cancer J 2018 10
  • 8(11):98/
    Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the
    Level of Pharmacokinetics, Pharmacodynamics and Metabolism. [15]
    Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N
    /Cancers (Basel) 2018 Jul
  • 10(7):/
    Effects of Inner Nuclear Membrane Proteins SUN1/UNC-84A and SUN2/UNC-84B on
    the Early Steps of HIV-1 Infection. [16]
    Schaller T, Bulli L, Pollpeter D, Betancor G, Kutzner J, Apolonia L, /et al/
    /J. Virol. 2017 10
  • 91(19):/
    With me or against me: Tumor suppressor and drug resistance activities of
    SAMHD1. [17]
    Herold N, Rudd SG, Sanjiv K, Kutzner J, Myrberg IH, Paulin CBJ, /et al/
    /Exp. Hematol. 2017 08
  • 52():32-39/
    SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
    Herold N, Rudd SG, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, /et al/
    /Cell Cycle 2017 Jun
  • 16(11):1029-1038/
    Improved Local Control by Extensive Surgery in High-Risk Neuroblastoma May Be
    Dependent on Adjuvant Radiotherapy. [19]
    Stenman J, Herold N, Svensson PJ, Kogner P
    /J. Clin. Oncol. 2017 06
  • 35(17):1965-1966/
    SAMHD1 is a barrier to antimetabolite-based cancer therapies. [20]
    Rudd SG, Schaller T, Herold N
    /Mol Cell Oncol 2017
  • 4(2):e1287554/
    Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for
    hematological malignancies. [21]
    Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, /et al/
    /Nat. Med. 2017 Feb
  • 23(2):256-263/
    Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha
    Interferon-Induced Antiviral Factors. [22]
    Bulli L, Apolonia L, Kutzner J, Pollpeter D, Goujon C, Herold N, /et al/
    /J. Virol. 2016 08
  • 90(16):7469-7480/
    The Early Bird Catches the Worm--Can Evolution Teach us Lessons in Fighting
    HIV? [23]
    Schaller T, Herold N
    /Curr. HIV Res. 2016
  • 14(3):183-210/
    HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the
    plasma membrane and does not require endocytosis. [24]
    Herold N, Anders-Ößwein M, Glass B, Eckhardt M, Müller B, Kräusslich HG
    /J. Virol. 2014 Dec
  • 88(24):13956-70/


  • Main supervisor PhD (Nikolaos Tsesmetzis)
    Co-supervisor PhD (Hajar Ali Mohammed Ba Omar, Fredrik Sundquist, Maria
    Alpman Sjöborg)
    Main supervisor Medical Degree Project (Aliyya Haciyeva, Julia Bladh)
    PhD course organiser /Translational Paediatric Oncology in the Era of
    Immunotherapy and Omics /(
    [1], [2])


All other publications



  • Assistant Professor, Department of Women's and Children's Health, Karolinska Institutet, 2020-2025

Degrees and Education

  • Docent, Karolinska Institutet, 2021

News from KI

Events from KI